Department of Cardiology, Affiliated Hospital of Inner Mongolia Medical University, China.
Ann Acad Med Singap. 2021 Jun;50(6):474-480. doi: 10.47102/annals-acadmedsg.2020505.
The apolipoprotein E () gene is a promising candidate for the diagnosis of hyperlipoproteinaemia and atherosclerosis. Polymorphisms in have been reported to result in differential efficacies of statin drugs in atherosclerotic cardiovascular disease.
We classified the genotypes of 225 patients treated with atorvastatin, and analysed the relation between genotypes and serum lipid levels.
The baseline serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were significantly lower in carriers of ε3 than of ε4 genotypes. The serum levels of TC and LDL-C decreased significantly after 1 month of atorvastatin treatment. Atorvastatin has a higher significant effect in reducing serum TC and LDL-C levels in patients with the ε4 genotype.
Polymorphism in the gene is related to the efficacy of atorvastatin in reducing the serum levels of TC and LDL-C.
载脂蛋白 E() 基因是诊断高脂血症和动脉粥样硬化的有前途的候选基因。已经报道 中的多态性导致他汀类药物在动脉粥样硬化性心血管疾病中的疗效存在差异。
我们对 225 例接受阿托伐他汀治疗的患者进行了 基因型分类，并分析了基因型与血清脂质水平之间的关系。
携带 ε3 基因型的患者的总胆固醇 (TC) 和低密度脂蛋白胆固醇 (LDL-C) 的基线血清水平明显低于携带 ε4 基因型的患者。阿托伐他汀治疗 1 个月后，TC 和 LDL-C 血清水平显著下降。携带 ε4 基因型的患者，阿托伐他汀降低 TC 和 LDL-C 血清水平的效果更为显著。
基因多态性与阿托伐他汀降低 TC 和 LDL-C 血清水平的疗效有关。
